A Herb-drug interaction study: Screen the inhibitory effects of Insulin plant extract on rat liver CYP2D6 isoenzyme upon concurrent administration of Aripiprazole
Aripiprazole belongs to the atypical antipsychotic category of drug. Cytochrome2D6 (CYP2D6) is one of the prominent enzymes that play a key role in the metabolism of Aripiprazole and further formation of an active metabolite, Dehydroaripiprazole takes place. Patients under the treatment with this potent moiety have been reported with the high blood glucose level as a side effect. In addition to this, literature suggests that the leaves of Insulin plant (Costus igneus) are usually administered by diabetic patients (2-3 times) to manage the sugar level without concerning to the physicians. There might be probability while concurrent administration of (Aripiprazole and Insulin plant leaves), leaves inhibit the enzyme and ultimately Dehydroaripiprazole exhibit poor pharmacological action. Hence, the present work was done to investigate the inhibitory effect of Insulin plant extract (IPE) on CYP2D6, with the co-administration of Aripiprazole (to examine the changes in a metabolite of Aripiprazole). In order to carry out this protocol firstly, IPE was prepared by the successive extraction method. Methanolic extract of Insulin plant was found enriched with the Quercetin, which was used as a marker to carry out this study. Presence of Quercetin was confirmed with the Ultra-violet spectroscopy (UV) and High-performance liquid chromatography (HPLC) analytical methods. Characterization of Aripiprazole was done with the help of different analytical tools such as: HPLC, melting point, and UV. Aripiprazole alone and with the several dilutions of IPE were incubated using isolated rat liver microsome (RLM) and analyzed using HPLC. HPLC data demonstrated that the, mixture of IPE+Aripiprazole (herb and drug in liver microsomes), in comparison to Aripiprazole+RLM (alone drug in liver microsomes) has not shown any significant inhibition of the enzyme, and inhibitory concentration (IC50) value found to be 4.49µg/ml. Therefore this study concluded that IPE has shown safe results even at the highest clinical dose after oral administration i.e., 20-1000µg/ml and did not show any significant CYP2D6 inhibition. Nevertheless, to confirm these observations, inclusion of in vivo studies will be advantageous. As per our knowledge, this is the first attempt made on the detection of Herb- Drug interactions (HDI’S) between Insulin plant and Aripiprazole.
2. Zhou, S.-F. et al. Identification of drugs that interact with herbs in drug development, Drug discovery today. Elsevier. 2007; 12(15–16):664–673. https://doi.org/10.1016/j.drudis.2007.06.004
3. Chung, V. C. H. et al. Do patients tell their clinicians they are using both prescribed and over the counter allopathic and traditional medicines? European Journal of Integrative Medicine. Elsevier. 2011; 3(4):e289–e298. https://doi.org/10.1016/j.eujim.2011.09.008
4. Hu, Z. et al. Herb-drug interactions, Drugs. Springer. 2005; 65(9):1239–1282. https://doi.org/10.2165/00003495-200565090-00005
5. Fugh-Berman, A. Herb-drug interactions, The Lancet. Elsevier. 2000; 355(9198):134–138. https://doi.org/10.1016/S0140-6736(99)06457-0
6. Services, U. S. D. of H. and H. Guidance for Industry: Drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2012; 39–40.
7. Kamble, B. et al. Determination of gymnemagenin in rat plasma using high‐performance liquid chromatography–tandem mass spectrometry: application to pharmacokinetics after oral administration of Gymnema sylvestre extract, Biomedical Chromatography. Wiley Online Library. 2013; 27(5):669–675. https://doi.org/10.1002/bmc.2845
8. Shapiro, D. A. et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology, Neuropsychopharmacology. Nature Publishing Group. 2003; 28(8):1400. https://doi.org/10.1038/sj.npp.1300203
9. “Product information for Abilify Aripiprazole Tablets & Orally Disintegrating Tablets”. TGA eBusiness Services. Bristol-Myer Squibb Australia pvt Ltd. 1 November 2012. Retrieved 22 October 2013.
10. “Abilify (Aripiprazole) - Clinical Pharmacology”.DrugLib.com. 14 February 2007. Retrieved 8 December 2008.
11. “Abilify”. The American society of Health-System Pharmacists. Retrieved 3 April 2011.
12. Raaz K Maheshwari, Bhanwar Lal Jat, Urmila Choudhary, Rajnee Bina Rani. Biomedicinal sovereignty of prunes for gastrointestinal ailments therapy. International journal of medicinal and pharmaceutical research, 2014; 2(3):669-674.
13. Satyanarayan ND, Mohammedsiraj mirji, Anantacharya and sanjeevkumar Giri. Amylase inhibitory activity of costus igneus leaf extract. International research journal of pharmaceutical and applied sciences, 2015; 1(5):12-15.
14. Kala, S. Antimicrobial Activity of Coleus For skohlii (Wild) Briq and Costus igneus NE Br. Journal of Pharmacy and Biological Science. 2014; 9:01-06.
15. Devi D, Urooj A. Nutrient profile and antioxidant components of Costus speciosus Sm. And Costus igneus Nak. Indian Journal of Natural Products and Resources. 2010; 1(1):116-8.
16. Borse SP, Kamble BB. Effect of Ayurvedic Rasayana botanicals on CYP3A4 isoenzyme system. Journal of Integrative medicine, 2015; 13(3): 165-172. https://doi.org/10.1016/S2095- 4964(15)60173-X
17. Lee C. A. et al. CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-Cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4, Archives of Biochemistry and Biophysics. Elsevier, 1995; 319(1):157–167. https://doi.org/10.1006/abbi.1995.1278
18. Thakkar R. S. et al. A chromatographic determination of Aripiprazole using HPLC and UPLC: A comparative validation study, Indian journal of pharmaceutical sciences. Medknow Publications. 2011; 73(4):439. https://dx.doi.org/10.4103%2F0250-474X.95638
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).